BioCentury | Mar 6, 2021
Politics, Policy & Law

PTAB expected to get a Supreme pass

...CRISPR technology between the Broad Institute of MIT...
BioCentury | Mar 5, 2021
Translation in Brief

A stem cell therapy for brain metastases in breast cancer; plus a nanoparticle gene editing delivery tech and more

...after a single dose. The method, developed by Tufts University and the Broad Institute of MIT...
...RTT) – Methyl CpG binding protein 2 Danielle Golovin Harvard Medical School AMASA Technologies Inc. Tufts University Broad Institute of MIT...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

...same time.Orna licensed its foundational IP, developed in the lab of co-founder Daniel Anderson, from the Massachusetts Institute of Technology.Barnes...
BioCentury | Feb 11, 2021
Emerging Company Profile

BigHat: AI for antibody optimization beyond target engagement

...than IgG. Before BigHat, Greenside was an associate computational biologist at the Broad Institute of MIT...
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

...California group and the Broad Institute of MIT...
BioCentury | Jan 30, 2021
Translation in Brief

Gladstone-UCSF research center to focus on brain diseases; plus a mammography-based prediction algorithm, PharmaMar and an intracellular glycoprotein that blocks phagocytosis

...uses mammography images to predict breast cancer risk. In a Science Translational Medicine publication, a team led by Massachusetts Institute of Technology...
...plitidepsin Veklury, remdesivir (GS-5734) Icahn School of Medicine at Mount Sinai University of California San Francisco PharmaMar S.A. Gilead Sciences Inc. Massachusetts Institute of Technology University...
BioCentury | Jan 30, 2021
Distillery Therapeutics

CRISPR base editing to treat progeria

...Tenn.email: jonathan.d.brown@vumc.orgCONTACT: David R. Liu, Broad Institute of MIT and Harvard, Cambridge, Mass.email: drliu@fas.harvard.edu Claire Quang Broad Institute of MIT...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...advisory board members include immuno-oncology pioneers Jim Allison and Padmanee Sharma of MD Anderson Cancer Center, Massachusetts Institute of Technology...
BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

...director in the post-War era. Lander, president and founding director of the Broad Institute of MIT...
...and Alphabet Inc. (NASDAQ:GOOG). Zuber is VP for research at the Massachusetts Institute of Technology and leader of MIT’s...
...staff of the U.S. Senate Committee on Commerce, Science and Transportation. C. Simone Fishburn NIH Broad Institute of MIT...
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...perivascular epithelioid cell tumors. Microsoft joins Broad Institute, Verily on open-source research platformThe Broad Institute of MIT...
...Bioscience S.A.S. Biogen Inc. Adaptive Biotechnologies Corp. AstraZeneca plc Aadi Bioscience Inc. EOC Pharma Group Verily Life Sciences LLC Broad Institute of MIT...
Items per page:
1 - 10 of 1295
BioCentury | Mar 6, 2021
Politics, Policy & Law

PTAB expected to get a Supreme pass

...CRISPR technology between the Broad Institute of MIT...
BioCentury | Mar 5, 2021
Translation in Brief

A stem cell therapy for brain metastases in breast cancer; plus a nanoparticle gene editing delivery tech and more

...after a single dose. The method, developed by Tufts University and the Broad Institute of MIT...
...RTT) – Methyl CpG binding protein 2 Danielle Golovin Harvard Medical School AMASA Technologies Inc. Tufts University Broad Institute of MIT...
BioCentury | Feb 27, 2021
Emerging Company Profile

Orna: turning circular RNAs into therapies

...same time.Orna licensed its foundational IP, developed in the lab of co-founder Daniel Anderson, from the Massachusetts Institute of Technology.Barnes...
BioCentury | Feb 11, 2021
Emerging Company Profile

BigHat: AI for antibody optimization beyond target engagement

...than IgG. Before BigHat, Greenside was an associate computational biologist at the Broad Institute of MIT...
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

...California group and the Broad Institute of MIT...
BioCentury | Jan 30, 2021
Translation in Brief

Gladstone-UCSF research center to focus on brain diseases; plus a mammography-based prediction algorithm, PharmaMar and an intracellular glycoprotein that blocks phagocytosis

...uses mammography images to predict breast cancer risk. In a Science Translational Medicine publication, a team led by Massachusetts Institute of Technology...
...plitidepsin Veklury, remdesivir (GS-5734) Icahn School of Medicine at Mount Sinai University of California San Francisco PharmaMar S.A. Gilead Sciences Inc. Massachusetts Institute of Technology University...
BioCentury | Jan 30, 2021
Distillery Therapeutics

CRISPR base editing to treat progeria

...Tenn.email: jonathan.d.brown@vumc.orgCONTACT: David R. Liu, Broad Institute of MIT and Harvard, Cambridge, Mass.email: drliu@fas.harvard.edu Claire Quang Broad Institute of MIT...
BioCentury | Jan 15, 2021
Product Development

Delfi and Earli series A rounds show there’s room for new entrants in early cancer detection

...advisory board members include immuno-oncology pioneers Jim Allison and Padmanee Sharma of MD Anderson Cancer Center, Massachusetts Institute of Technology...
BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

...director in the post-War era. Lander, president and founding director of the Broad Institute of MIT...
...and Alphabet Inc. (NASDAQ:GOOG). Zuber is VP for research at the Massachusetts Institute of Technology and leader of MIT’s...
...staff of the U.S. Senate Committee on Commerce, Science and Transportation. C. Simone Fishburn NIH Broad Institute of MIT...
BioCentury | Jan 12, 2021
Deals

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

...perivascular epithelioid cell tumors. Microsoft joins Broad Institute, Verily on open-source research platformThe Broad Institute of MIT...
...Bioscience S.A.S. Biogen Inc. Adaptive Biotechnologies Corp. AstraZeneca plc Aadi Bioscience Inc. EOC Pharma Group Verily Life Sciences LLC Broad Institute of MIT...
Items per page:
1 - 10 of 1295